15 PGDH Antibody (YA7632)

Cat. No.: HY-P87947: Ficha de datos User Guide for Antibodies
FAQs
Technical Support

15 PGDH Antibody (YA7632) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to 15 PGDH.

Para uso exclusivo en investigación. No vendemos a pacientes.

Tamaño		Stock
50 μL		Obtener un presupuesto
100 μL		Obtener un presupuesto

* Seleccione Cantidad antes de agregar artículos.

WB: Western Blot;
IHC-P: Immunohistochemistry-Paraffin;
IHC-F: Immunohistochemistry-Frozen;
ICC/IF: Immunocytochemistry/Immunofluorescence;
IF-Tissue: Immunofluorescence-Tissue;
mIHC: Multiplex Immunohistochemical;
IP: Immunoprecipitation;
ChIP: Chromatin Immunoprecipitation;
FC: Flow Cytometry;
ELISA: Enzyme Linked Immunosorbent Assay

Product Detail
Background
Descripciòn

Descripciòn

15 PGDH Antibody (YA7632) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to 15 PGDH.

Host

Rabbit

Clonality

Recombinant

Peso molecular

Predicted band size: 29 kDa;

Observed band size: 29 kDa

Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.

Species Reactivity

Human

SwissProt ID

P15428

Immunogen

A synthesized peptide derived from human 15 PGDH

Application &
Dilution Ratio

Application	Dilution Ratio
WB WB: Western Blot	1:500-2000
IHC-P IHC-P: Immunohistochemistry-Paraffin	1:100-200
IHC-F IHC-F: Immunohistochemistry-Frozen	1:100-200
IF-Tissue IF-Tissue: Immunofluorescence-Tissue	1:50-200
FC FC: Flow Cytometry	1:50-100
ICC/IF ICC/IF: Immunocytochemistry/Immunofluorescence	1:50-200

Sensitivity	Endogenous	Pureza	affinity purified by Protein A
Conjugation	Non-conjugated	Modification	Unmodified
Isotype	IgG

Appearance

Liquid

Formulation

Supplied in 10mM phosphate buffered saline(pH 7.4) with 150mM sodium chloride, 0.05% BSA, 0.02% Proclin300 and 50% glycerol.

Storage & Stability

Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

Envío

Shipping with blue ice.

Background

Function：Catalyzes the NAD-dependent dehydrogenation (oxidation) of a broad array of hydroxylated polyunsaturated fatty acids (mainly eicosanoids and docosanoids, including prostaglandins, lipoxins and resolvins), yielding their corresponding keto (oxo) metabolites (PubMed:10837478, PubMed:16757471, PubMed:16828555, PubMed:21916491, PubMed:25586183, PubMed:8086429). Decreases the levels of the pro-proliferative prostaglandins such as prostaglandin E2 (whose activity is increased in cancer because of an increase in the expression of cyclooxygenase 2) and generates oxo-fatty acid products that can profoundly influence cell function by abrogating pro-inflammatory cytokine expression (PubMed:15574495, PubMed:25586183). Converts resolvins E1, D1 and D2 to their oxo products, which represents a mode of resolvin inactivation. Resolvin E1 plays important roles during the resolution phase of acute inflammation, while resolvins D1 and D2 have a unique role in obesity-induced adipose inflammation (PubMed:16757471, PubMed:22844113)

Subcellular Localization：Cytoplasm

Expression：
Tissue_Specificity: Detected in colon epithelium (at protein level)
Induction: Down-regulated by cortisol, dexamethasone and betamethasone. Down-regulated in colon cancer. Up-regulated by TGFB1

Isoforms & Post-Translational Modification：P15428 has 5 isomers: P15428-1: 28977 Da (predicted); P15428-2: 19284 Da (predicted); P15428-3: 15696 Da (predicted); P15428-4: 15534 Da (predicted); P15428-5: 21526 Da (predicted).

Subunit：Homodimer

Documentación

User Guide for Antibodies (1077 KB)